76PCorrelative analyses of serum biomarkers and efficacy outcomes in the randomized phase II trial of lenvatinib (LEN), everolimus (EVE), or LEN+EVE in patients with metastatic renal cell carcinoma. (23rd October 2018) - Lee, C-H; Motzer, R J; Glen, H; Michaelson, M D; Larkin, J; Minoshima, Y; Kanekiyo, M; Dairiki, R; Sachdev, P; Dutcus, C E; Funahashi, Y; Voss, M H